Drug discovery and development company Kura Oncology announced an underwritten public offering of 5.7 million common shares and pre-funded warrants to purchase up to three million common shares. The company aims to raise approximately USD 100 million at a price of USD 11.50 per share.
Additionally, the company has granted underwriters a 30-day option to purchase an additional 1.3 million shares at the same price. The offering is expected to close on June 16, 2023, and the net proceeds will be utilized for various purposes, including drug candidate development and expanding clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.